http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
내시경역행담췌관조영술과 간동맥내 화학요법 후 소실된 담관내 간세포암 1예
조영윤 ( Young Youn Cho ),이상협 ( Sang Hyub Lee ),이재우 ( Jae Woo Lee ),박진명 ( Jin Myung Park ),류지곤 ( Ji Kon Ryu ),김용태 ( Yong Tae Kim ),윤창진 ( Chang Jin Yoon ),김혜령 ( Haer Young Kim ) 대한소화기학회 2014 대한소화기학회지 Vol.63 No.5
Invasion of the bile duct by hepatocellular carcinoma (HCC), which is called intrahepatic bile duct HCC, is rare and has a poor prognosis. Early diagnosis and surgical resection is important for treatment. A 58-year-old man who underwent hepatic resection for HCC 4 years ago and received transarterial chemoembolization (TACE) 2 years after the operation for recurred HCC presented with jaundice. CT scan revealed a tumor in the common bile duct without intrahepatic lesion. Therefore, ERCP was done to perform biopsy and biliary drainage. Histological examination was compatible with hepatocellular carcinoma. However, the tumor could not be visualized at angiography and thus, only transarterial chemoinfusion was performed without embolization. The tumor had disappeared on follow-up CT scan, and the patient has been disease free for 23 months without evidence of recurrence. Herein, we report a case of intrahepatic bile duct HCC which disappeared after ERCP.
간세포암종에서 지방산 결합 단백질의 발현 소실과 예후와의 관계
김혜령 ( Haer Young Kim ),이혜정 ( Hye Jung Lee ),박영년 ( Young Nyun Park ) 대한간암학회 2015 대한간암학회지 Vol.15 No.1
Background/Aims: Loss of liver fatty acid binding protein (LFABP) expression by immunohistochemistry is a useful marker for the identification of hepatocyte nuclear factor 1α (HNF1α)-inactivated hepatocellular adenomas; however, the expression status of LFABP in hepatocellular carcinomas (HCCs) is still unclear. We aimed to investigate the expression status of LFABP in HCCs and examine the clinicopathological characteristics of LFABP-negative HCCs. Methods: Immunohistochemical stains LFABP, K19 (mouse monoclonal, Dako, Glostrup, Denmark) and EpCAM (mouse monoclonal, Calbiochem, Darmstadt, Germany) were performed on tissue microarray sections from 188 surgically resected HCCs, and the association between LFABP expression status and the clinicopathological features, survival and “stemness”-related marker expression status were analyzed. Results: Loss of LFABP expression was noted in 30 (16%) out of 188 HCCs. LFABP-negative HCCs were associated with a decreased recurrence-free survival (LFABP-negative: 17.0 ± 4.84 months [95% confidence interval [CI]: 7.5.26.5 months] versus LFABP-positive: 51.0 ± 8.7 months [95% CI: 34.0.68.0 months]; P=0.004). HCCs with LFABP expression loss were more frequently larger and showed more frequent vascular invasion, although not statistically significant; and an inverse correlation was seen between LFABP expression and K19 expression status (P=0.001). Conclusions: Loss of LFABP expression is seen in HCCs, and is associated with a decreased recurrence-free survival. (Journal of Liver Cancer 2015;15:30-35)
( Hee Sup Kim ),( Sook Hyang Jeong ),( Je Hyuck Jang ),( Hyung Joon Myung ),( Jin Wook Kim ),( Soo Mee Bang ),( Sang Hoon Song ),( Haer Young Kim ),( Hae Sun Yun ) 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.4
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV. (Korean J Hepatol 2011;17:323-327)